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ABSTRACTS
Autoimmune blistering diseases: clinical advances from basic research
John R. Stanley
Department of Dermatology, University of Pennsylvania, Philadelphia
The initial discovery, by immunofluorescence, of autoantibodies in pemphigus and
pemphigoid was critical in allowing us to dissect the pathophysiology of these diseases.
The understanding that these autoantibodies are pathogenic, either directly or indirectly, then
led to advanced techniques for diagnosis, prognosis, and therapy. In pemphigus, patients’
antibodies were used to clone the antigens, desmoglein (Dsg) 3 and desmoglein 1. Once
cloned, these molecules were used to develop an ELISA test that has shown to be valuable in
diagnosis and prognosis. Subsequently, a mouse with a genetic deletion of Dsg 3 was
engineered and has been used to develop an active mouse model of pemphigus, which has in
turn been used to further dissect the pathophysiology of disease and test innovative therapies.
Furthermore, the cloned antigens have been used to study the T cell involvement in disease,
which may lead to T cell therapy. The antigens have also been used to clone human
monoclonal antibodies from patients that have the potential to be useful for targeted therapy.
Additional studies of signal transduction in disease have suggested such pathways for another
type of targeted therapy. Similarly, the cloning of pemphigoid antigen and the antigens of
epidermoysis bullosa acquisita and cicatricial pemphigoid have given us reagents to develop
new diagnostic and therapeutic approaches. These observations point out the very long lag
time between discovery (immunofluorescence in 1964) and clinical advances (still continuing
in 2006) from that discovery.
Pemphigus
Masayuki Amagai
Department of Dermatology, Keio University School of Medicine
Pemphigus vulgaris (PV) is an autoimmune bullous disease caused by IgG autoantibodies
against desmoglein 3 (Dsg3). Previously we have generated an active disease model for PV by
a unique approach by adoptive transfer of Dsg3-/- lymphocytes to mice expressing Dsg3. To
explore the pathophysiological mechanism of autoantibody production in pemphigus, we are
investigating B cells as well as T cells specific for Dsg3 in mice. For B cell approach, we have
generated Dsg3-specific AK7 B cell transgenic mice and found that Dsg3-specific AK7 B cells
were detected in peripheral lymphoid organs without elimination or inactivation. However,
when AK23 mAb that is pathogenic and able to induce blisters was injected into AK7-Tr mice,
AK7 B cells disappeared from the peripheral lymphoid organs within a week following
development of PV phenotype. In contrast, when non-pathogenic AK7 or AK9 mAb was
injected, there was no disappearance of AK7 B cells. This finding suggests a novel tolerance
mechanism of eliminating self-reactive B cells induced by danger signals from the skin. For T
cell approach, we have isolated and characterized Dsg3-reactive CD4þ T cell clones. In
autoantibody-mediated autoimmune diseases, T cells were characterized only by reactivity to
autoantigens. In our passive transfer PV model, we are able to determine whether isolated T
cells clones are directly involved in the production of pathogenic anti-Dsg3 IgG. The
individual T-cell clones together with Dsg3-/- splenic B cells were transferred into Rag2-/-
mice. Some T cell clones were able to induce the PV phenotype, while the others fail to do so.
Further characterization of pathogenic and non-pathogenic Dsg3-specific T cells will clarify
uncovered mechanisms involving T cells in autoantibody production in pemphigus.
Bullous pemphigoid
Zhi Liu
Department of Dermatology, University of North Carolina at Chapel Hill, NC USA
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease characterized by
an inflammatory infiltrate and autoantibodies against the hemidesmosomal components
BP230 (BPAG1) and BP180 (BPAG2 or type XVII collagen). In vitro studies show that total BP
autoantibodies and affinity-purified BP180-specific autoantibodies induce dermal-epidermal
separation in the presence of complement and neutrophils. In the rabbit anti-murine BP180
(mBP180) IgG passive transfer model of BP, subepidermal blistering is triggered by anti-
mBP180 IgG and is dependent on the classical pathway of complement system. The classical
pathway activation leads to mast cell degranulation and subsequent neutrophil infiltration.
Neutrophil elastase, MMP-9 and plasmin released by neutrophils and other local cells
damage BP180 and other extracellular matrix components, resulting in BP blisters. To directly
test the pathogenicity of anti-BP180 autoantibodies, we generated a mouse strain in which the
mouse BP180NC14A is replaced with the human BP180NC16A, a domain harboring BP
dominant epitopes. The humanized BP180NC16A mice injected with BP180NC16A-specific
BP autoantibodies developed skin lesions that mimics human BP and the rabbit anti-mBP180-
induced BP clinically and immunohistologically. These animal models help us dissect disease
immunopathology and develop new therapeutic strategies for BP.
Human Bullous Pemphigoid Antigen 2 Transgenic Skin Elicits Specific IgG in Wild Type
Mice
Edit Olasz, Jooyoung Roh, Carole Yee, Ken Arita, Masashi Akiyama, Hiroshi Shimizu,
Jonathan Vogel, Kim B. Yancey
Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA;
Dermatology Branch, DCS, NCI, NIH, Bethesda, MD, USA; Department of Dermatology,
Hokkaido University Graduate School of Medicine, Sapporo, Japan
Bullous pemphigoid antigen 2 (BPAG2) is targeted by autoantibodies in patients with bullous
pemphigoid (BP) and absent in patients with one type of epidermolysis bullosa. A keratin 14
promoter construct was used to produce transgenic (Tg) mice appropriately expressing human
BPAG2 (hBPAG2) in murine epidermal basement membrane (BM). Grafts of Tg skin placed on
gender-matched, syngeneic wild type (Wt) or MHC I / mice elicited IgG that bound
human epidermal BM and BPAG2. Production of such IgG in grafted mice was prompt
(detectable within 16þ 2 days), robust (titer41280), durable (present 4380 days), and
correlated with the involution and loss of Tg skin grafts. MHC II /mice grafted with Tg skin
did not develop anti-hBPAG2 IgG or graft loss indicating that MHC II:CD4þ T cell
interactions were crucial for these responses. Tg skin grafts on Wt mice developed
granulocyte-rich infiltrates, dermal edema, subepidermal blisters, and deposits of immunor-
eactants in epidermal BM. This model shows fidelity to alterations seen in patients with BP,
has relevance to immune responses that may arise in patients with epidermolysis bullosa
following BPAG2 gene replacement, and can be used to identify interventions that may block
production of IgG against proteins in epidermal BM.
T cell control in pemphigus and pemphigoid
Michael Hertl, Christian Veldman, Ru¨diger Eming
Department of Dermatology, Philipps University, Marburg, Germany
Current concepts support the idea that autoaggressive T helper cells are critical players in the
immune pathogenesis of pemphigus vulgaris (PV) and bullous pemphigoid (BP) by fostering
auto-ab production by auto-aggressive B cells. Activation of autoreactive T cells in PV and BP
is restricted by distinct HLA class II alleles that are prevalent in individuals with these
disorders. Autoreactive T cells are not only present in patients but can be also detected in
healthy individuals that carry the disease-associated HLA class II alleles. Recently, a subset of
autoreactive T cells with remarkable regulatory function was identified in healthy individuals
and to a much lesser extent in patients with PV suggesting that the occurrence of autoimmune
bullous disorders may be linked to a dysfunction of regulatory T cells. These findings suggest
that PV is presumably the consequence of a loss of tolerance against desmogleins on the B cell
rather than the T cell level. In PV and BP, autoreactive T cells recognize restricted epitopes of
the desmogleins and of BP180/BP230, respectively, that are also targeted by autoreactive B
cells. Intimate T/B cell interaction is required for autoantibody production because depletion
of B cells by the anti-CD20 monoclonal antibody, rituximab, also modulates the activation of
autoreactive Th1 and Th2 cells in PV. The prompt clinical response of PV patients on
rituximab treatment which is often seens prior to a decrease of serum autoantibodies may thus
be related to an inhibitory effect on autoreactive T cells. There seems to be an equilibrium of
autoaggressive Th2 and regulatory T cells because antisense-induced inhibition of the
regulatory gene, Foxp3, leads to a phenotype typical for Th2 cells. The availability T cell-
specific markers, such as HLA-DRß*0402-Dsg-tetramers, will hopefully facilitate to monitor
autoreactive T cells and may thus serve as a sensitive marker for autoantigen-specific immune
interventions.
Apoptosis in Pemphigus
Carlo Pincelli
Institute of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
Apoptotic keratinocytes are present in perilesional, yet undetached, pemphigus skin. We have
also shown that pemphigus sera from untreated, but not from steroid treated patients induce
apoptosis in cultured keratinocyte. FasL levels are strikingly increased in sera from untreated
pemphigus patients, as compared to either treated patients or controls. Pemphigus sera-
induced keratinocyte apoptosis is partially prevented by pretreatment with either caspase-8
inhibitor or anti-FasL neutralizing antibody. Moreover, caspase-8 cleavage induced by
untreated pemphigus sera is partially inhibited by anti-FasL antibody. Finally, untreated
pemphigus sera or rFasL induce the cleavage of desmoglein 3 (dsg 3). Taken together these
results suggest that, in pemphigus, keratinocytes undergo apoptosis before detachment, and
that increased levels of FasL in pemphigus sera stimulate the activation of the caspase-8
extrinsic apoptotic pathway and the cleavage of dsg 3. Immunoglobulin Therapy (IVIg) down-
regulate apoptotic genes and prevent acantholysis both in vitro and in vivo, thereby
ameliorating pemphigus.
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Autoantibody profile and epitope spreading in bullous pemphigoid
Giovanna Zambruno
Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell’Immacolata, IRCCS,
Rome, Italy
Bullous pemphigoid (BP) is an autoimmune subepidermal bullous disease associated with
circulating and tissue-bound autoantibodies recognizing an hemidesmosomal component,
BP180 antigen. BP patients’ sera contain IgG autoantibodies mainly directed to an
extracellular immunodominant region, the NC16A domain, but also to additional antigenic
sites located both in the intracellular and extracellular domains of BP180. Using a random
epitope library displayed on lphage, we have selected several BP180 epitopes that are
significantly recognized by BP sera. In addition, specific autoantibody reactivity has been
associated with different clinical phenotypes and disease severity. To investigate the
dynamics of the humoral immune response against BP180, we have then employed an
experimental mouse model in which the skin of transgenic mice expressing the human
BP180 molecule in the epidermal basement membrane is grafted onto syngeneic wild type
animals, generating a specific anti-BP180 immune response. Evaluation of the reactivity of
grafted mice sera against several BP180 epitopes at different time points after grafting showed
the frequent development of an intramolecular epitope spreading phenomenon against
human BP180, with recognition of extracellular domain epitopes preceding that of
intracellular ones. In parallel, analysis of data from a prospective multicenter study of BP
autoantibody profile in disease course indicated that reactivity against multiple epitopes,
including intracellular ones, is already present at diagnosis in the majority of BP patients and
that an ‘‘epitope spreading phenomenon’’ occurs in some patients during disease course.
Altogether these findings support the current view that the humoral immune response against
BP180 in BP at first targets extracellular epitopes which appear crucial to disease
development, and suggest that ‘‘epitope spreading’’ is an early phenomenon which can
occur at disease onset or even in the prodromal disease phase. Further studies are needed to
assess the possible role of these additional antigenic sites in disease pathogenesis.
Characterization of Novel Signaling Pathways Downstream of Non-desmoglein Targets of
Pathogenic Autoantibodies In Pemphigus Vulgaris
Alex I. Chernyavsky and Sergei A. Grando
Department of Dermatology, University of California, Davis, CA, USA
Although it is accepted that pemphigus antibody binding to keratinocytes (KC) evokes an
array of intracellular biochemical events resulting in cell detachment and death, the triggering
events remain obscure. It has been postulated that binding of pemphigus vulgaris IgG (PVIgG)
to KC induces ‘‘desmosomal’’ signaling. Since in contrast to integrins and classical cadherins,
desmogleins are not known to elicit intracellular signaling, and since PV patients also produce
non-desmosomal autoantibodies, we investigated the roles of desmoglein (Dsg) 1 and 3 in
PVIgG-induced signaling. The time-course biochemical and morphologic studies of KC
treated with PVIgG demonstrated that the activity of src peaked at 30 min, EGFR at 60 min and
p38 at 240 min. The src inhibitor PP2 decreased EGFR and p38 activities by B50% and
B30%, respectively, indicating that in addition to src, binding of PVIgG to KC engages other
signaling mechanisms. The shrinkage of KC (cell volume reduction) became significant at
120 min, keratin aggregation at 240 min, and an increase of TUNELþKC at 360 min.
Pretreatment of KC with PP2 blocked PVIgG-dependent cell shrinkage by B30%, keratin
aggregation byB45% and TUNEL positivity byB45%, whereas the p38 inhibitor PD169316
inhibited these effects by B10%, B20% and 70%, respectively. Transfection of KC with
small interfering RNAs that inhibited expression of Dsg1 or Dsg3 proteins by 480%, in both
cases blockedB50% of p38 activity but did not significantly alter PVIgG-dependent raise in
src and EGFR activities. These results indicate that activation of p38 is a late signaling step
associated with collapse of the cytoskeleton and dissassembly of desmosomes caused by
upstream events involving src and EGFR. Therefore, the early events appear to be triggered by
non-Dsg antibodies.
The ‘‘Basal Cell Shrinkage’’ Hypothesis - A New Explanation For Acantholysis In
Pemphigus Vulgaris
Jean-Claude Bystryn, Sergei Grando
Department of Dermatology, NYU School of Medicine, New York, NY & University of
California, Davis, CA
We propose a new hypothesis to explain acantholysis in pemphigus vulgaris (PV) and its
restriction to the basal cell layer. The current explanation for acantholysis, that it results from
anti-desmoglein antibodies interfering with the adhesive properties of desmosomes, is not fully
satisfactory. If correct, keratinocytes should separate first at the desmosomes where desmoglein
1 and 3 are located. The reverse actually occurs. By electron microscopy cells separate first in
interdesmosomal areas, where there are no desmosomes. Even in the final stage of acantholysis
when keratinocytes are fully separated, desmosomes can still be attached to each other at the
end of stretched out portions of the cell membrane. In addition, the earliest morphological
event in acantholysis is the separation and retraction of tonofilaments from desmosomes. Based
on these observations, we propose that acantholysis results from the collapse of the cytoskeletal
structure of basal keratinocytes. As a result, basal cells shrink and pull away from each other
more strongly than desmosomes can hold them together.
We further propose that acantholysis is limited to basal cells because these cells shrink more
than suprabasal keratinocytes. This could occur either because basal cells are less rigid and
shrink more readily than suprabasal keratinocytes when their cytoskeleton is altered, because
their cytoskeletal structure is altered to a greater extent by signaling events, or because
different signaling events are triggered in basal cells when they interact with pemphigus
antibodies.
We hope that by challenging current dogma this hypothesis will stimulate novel approaches
to study the causes of pemphigus and open new avenues to treat the disease.
Sustained expression of the proto-oncogene c-Myc in Pemphigus vulgaris: pathomechan-
ism and diagnostic tool
Eliane J. Mu¨ller, L. Williamson, T. Hunziker, M.M. Suter
We recently reported that PV autoantibody binding to desmoglein (Dsg) 3 of keratinocytes
triggers pathogenic nuclear c-Myc accumulation and hyperproliferation in skin and mucous
membranes of pemphigus vulgaris (PV) patients. The cascade leading to c-Myc transcription
ranges from a transient, enhanced turn-over of cell surface exposed, non-keratin-anchored
Dsg3 and associated plakoglobin (PG), through to depletion of nuclear PG, and as one of the
consequences, abrogation of PG-mediated c-Myc suppression. In human and canine PV
patients (10/10) this results in pathogenic c-Myc overexpression and hyperproliferation in all
targeted tissues, including the stem cell compartment. This phenomenon is specific for PV as
it is not observed in other autoimmune bullous diseases, skin disorders with known
hyperproliferation, or toxic epidermal necrolysis (TEN), a clinically relevant differential
diagnosis of PV. Moreover, disease progression in a patient with co-existing PV/pemphigus
foliaceus (PF) correlated with nuclear c-Myc accumulation in keratinocytes that was
detectable before the formation of typical acantholytic blisters, and significantly decreased
upon successful treatment with systemic glucocorticosteroids. Together these data provide a
novel insight into PV pathogenesis that combine the steric hindrance/cell signaling hypothesis
mediated via soluble Dsg3/PG and further identify novel therapeutic targets and diagnostic
tools.
Genetic polymorphisms in pemphigus
Danie`le Gilbert
Rouen, France
In most autoimmune diseases, environmental and genetic factors contribute to their
susceptibility. Clues to the underlying genetic susceptibility should be provided by
epidemiological studies, including differences in the prevalence in different populations
and familiar aggregation. In pemphigus, a large body of data has accumulated which supports
genetic predisposition, in particular concerning case-control studies which allow to test an
association between a given risk factor and a disease. This approach consistently
demonstrated that the MHC locus is associated with both pemphigus vulgaris and pemphigus
foliaceus. PV was found to be associated with DR4 and DR14 and, more precisely, with
DRB1*0402 and DRB1*1401 subtypes. Susceptibility to PF was correlated with the presence
of DR4, DR14 and DR1 alleles but in contrast to PV no single allele was shown to be
associated with the disease. Four informative microsatellite markers were also detected,
mapping into an HLA-G gene. Among genes coding for molecule thought to play a role in the
autoimmune process, the gene encoding the putative autoantigen could be polymorphic and
then, involved in the disease susceptibility. A single silent T to C transition at position 809 of
the coding sequence of DSG1 was shown to be significantly more frequent in both French and
Tunisian patients than in controls and, interestingly, a combination of HLA DR4 and C/C (809)
genotype conferred a stronger risk of PF development than either alone. A similar association
of 2 haplotypes of the DSG3 gene was observed in PV in British and Indian populations. Other
candidate genes, as IGH and IGL or cytokine genes were also demonstrated to be associated
with pemphigus. In conclusion, pemphigus, like other autoimmune diseases are complex and
polygenic disorders in which many genes, with various penetrance operate and interact to
control the disease process.
New Diagnostic Tools in Pemphigus
Takashi Hashimoto
Department of Dermatology, Kurume University School of Medicine
Pemphigus includes pemphigus foliaceus (PF) and mucosal dominant type and mucocuta-
neous type of pemphigus vulgaris (PV), as well as paraneoplastic pemphigus (PNP) and IgA
pemphigus. By enzyme-linked immunosorbent assay (ELISA) using baculoproteins of human
desmoglein 1 (Dsg1) and Dsg3, PF reacts with only Dsg1, mucosal dominant type of PV reacts
with only Dsg3, and mucocutaneous type of PV reacts with both Dsg1 and Dsg3.
Immunoprecipitation of Dsg3 swapped molecules using Dsg2 as a backbone has recently
been developed. This study is useful for determining the epitopes for PV sera. PNP react
strongly with both envoplakin and periplakin by Immunoblotting using epidermal extracts. By
Immunoblotting using domain specific recombinant proteins of envoplakin and periplakin,
PNP sera were shown to react with various domains of the two molecules. cDNA transfection
test to COS-7 cells using cDNAs of human desmocollin 1 (Dsc1)-Dsc3 showed that
subcorneal pustular dermatosis type of IgA pemphigus react with Dsc1. In addition, ELISA
using baculoproteins of Dsc1-3 can be used to detect anti-Dsc autoantibodies in the sera of
some atypical cases of pemphigus.
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New diagnostic tools in bullous pemphigoid: practical use and limitations of BP180- and
BP230-ELISA
Luca Borradori
Clinique de Dermatologie, Hoˆpitaux Universitaires, Gene`ve, Suisse
Enzyme-linked immunosorbent assays (ELISA) have recently been developed that allow the
rapid and easy detection of circulating autoantibodies against BP180 or BP230 in bullous
pemphigoid (BP). Since strong evidence exists indicating that anti-BP180 autoantibodies are
pathogenic, the investigators’ interest has focused on BP180. Specifically, the membrane-
proximal NC16A domain on the ectodomain of BP180 has been recognized to contain the
immunodominant antigenic sites. Therefore, most studies on the use of ELISA in BP have
employed recombinant proteins consisting of the NC16A domain of BP180 with or without
other portions of its ectodomain. Overall, the obtained data indicate that: (1) BP180-ELISA
exhibit high sensitivity and specificity and are superior to conventional diagnostic tools (i.e.,
immunofluorescence and immunoblotting studies); (2) levels of anti-BP180 autoantibodies
reflect disease severity and tend to parallel activity in the course of the disease; (3) the
reactivity profile with distinct BP180 epitopes is associated with distinct clinical phenotype
(e.g. mucosal involvement); (4) BP230-ELISA are less performant, but have confirmatory
diagnostic value. Nevertheless, there are a number of key questions that remain unanswered
concerning the practical usefulness of BP180-ELISA: (1) in differentiating BP from other
pruritic eruptions frequently occurring in elderly; (2) in patients’ management and guiding
therapy when compared to obvious clinical symptoms (e.g. itch); and (3) in predicting relapse.
It is hoped that the undergoing prospective studies in large cohorts of BP patients will provide
better insights into the value of these tests.
Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus
vulgaris (PEMPULS trial)
Mentink LF, Mackenzie MW, To´th GG, Laseur M, Lambert FPG, Veeger NJ, Cianchini G,
Pavlovic´ MD, Jonkman, MF
Center for Blistering Diseases, Department of Dermatology, University Medical Center
Groningen, University of Groningen, Groningen, The Netherlands
Background: Evidence for the adjuvant effect of high-dose-corticosteroid pulse therapy in the
treatment of pemphigus vulgaris is lacking by randomized controlled trial.
Objective: To determine the therapeutic effect of adjuvant dexamethasone pulse therapy
when given in addition to conventional treatment.
Design: A randomized placebo-controlled trial.
Setting: International European multi-center outpatient and inpatient study.
Patients: Of the 20 enrolled patients, 11 were randomized to the dexamethasone pulse (DP)
group and 9 to the placebo pulse (PP) group.
Interventions: Oral dexamethasone 300 mg pulses or placebo pulses 3 days per month.
During the intervention, both DP and PP groups received conventional treatment with
prednisolone 80 mg/day tapered over 19 weeks and azathioprine 3 mg/kg/day until end of
study. Monthly pulses were continued until prednisolone was tapered to zero.
Main outcome measures: Number of patients in remission, the time to and duration of
remission, cumulative prednisolone dose, and occurrence of adverse events during one year
of follow up.
Results: Eight of 11 patients treated with DP and all nine with PP reached remission. Mean
time to remission was 173 days with DP and 176 days with PP. The mean duration of
remission within the first year was 151 days for DP and 141 days for PP. Mean cumulative
prednisolone dose was 5300 mg in DP and 4882 mg in PP. Weight gain (45% of baseline)
occurred in 8 patients treated with DP, versus one patient on PP (Po0.01). No statistical
significant difference (P40.05) of an adjuvant effect of DP on remission of pemphigus
vulgaris was found.
Conclusion: In new pemphigus vulgaris patients, there was no benefit of adjuvant oral
dexamethasone pulse therapy given in addition to conventional treatment.
Rituximab in Pemphigus – German
experience
Nicolas Hunzelmann
University of Cologne, Department of Dermatology, 50924 Cologne, Deutschland
The treatment of severe, potentially life-threatening autoimmune blistering disorders such as
pemphigus is still challenging. In the pathogenesis of autoantibody mediated diseases B cells
are thought to play a decisive role. Thus, eradication of auto-reactive B cell clones, which we
could recently demonstrate in the peripheral circulation for the major pemphigoid antigen
Nc16a, might be an attractive therapeutic option. To deplete disease causing B cells that are
involved in autoantibody synthesis, we have treated pemphigus patients with the monoclonal
antibody rituximab directed against the B-lymphocyte surface antigen CD20. The significant
clinical improvement in all patients after rituximab was accompanied by a marked reduction
of the immunosuppressive co-medication. Rituximab treatment was well tolerated, adverse
effects such as nausea, vomiting, facial edema, chills or cough occurred mostly during the first
intravenous administration. Depletion of CD20 lymphocytes occurred rapidly after the
infusion of rituximab and was long-lasting. However, the antibody titre to desmogleins
correlated only in some patients with clinical improvement. This points to additional effects of
B-cell directed therapy on the autoimmune process observed also in other autoimmune
diseases, which to date are only poorly understood. In conclusion, clinical data reported by
several groups indicate that B-cell directed therapy may represent a major step forward in the
treatment of pemphigus.
Immunoadsorption in Pemphigus
Ru¨diger Eming
University of Marburg, Department of Dermatology and Allergology
Pemphigus represents a group of potentially life-threatening, chronic skin diseases
characterized by autoantibodies directed against desmoglein 1 and 3, transmembranous
components of the desmosomes. There is profound clinical and experimental evidence for the
pathogenicity of desmoglein-reactive IgG autoantibodies. Despite the use of high-dose
glycocorticoids combined with immunosuppressive adjuvants, the treatment of pemphigus
remains a challenging problem. The therapeutic removal of serum IgG by immunoadsorption
has been proven to be effective in the treatment of severe pemphigus. In a recent study we
could show that immunoadsorption using the synthetic ligand PGAM 146 (Globaffins) with a
high affinity for the Fc-portion of human IgG is capable of reducing the level of desmoglein-
specific serum IgG by 70–80% in one treatment cycle consisting of four immunoadsorptions
on consecutive days. Immunoadsorption has been applied in an adjuvant treatment regiment
combined with high-dose glycocorticoids (1–2 mg/kg/d) and immunosuppressive adjuvants
mostly mycophenolate mofetile or azathioprine. Compared to the conventional immuno-
suppressive treatment, the dose of systemic glycocorticoids can be tapered significantly faster
after immunoadsorption. Especially patients with high autoantibody titres who are resistant to
conventional treatment show good clinical responses to immunoadsorption. Recently the
monoclonal anti-CD20 antibody rituximab demonstrated excellent clinical results in treating
patients with recalcitrant pemphigus. Thus current investigations evaluate the combination of
rapid removal of autoantibodies by immunoadsorption followed by B cell depletion using the
anti-CD20 antibody to obtain long term control of the disease. In conclusion, immunoad-
sorption has proven to be a safe and well tolerated therapeutic option in the treatment of
severe pemphigus.
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Intravenous Immunoglobulin (IVIg) Therapy in autoimmune mucocutaneous blistering
diseases (AMBDs): Is there evidence-based efficacy?
Razzaque Ahmed
Center for Blistering Diseases, Boston, USA
The purpose of this study is to determine if the current information on the use of IVIg in
AMBDs demonstrates that it is evidence based effective therapy. This was accomplished by
defining evidence based medicine. Then a sequential analysis was performed. The first step
required formulating a question. The question for this evidence based examination of data on
IVIg was: Is there evidence that IVIg is efficient in treating patients with AMBDs? Only those
patients were included, in whom the diagnosis was based on histology and supportive
immunopathological studies and in whom adequate follow-up was present. Then the
evidence was researched. Thereafter the evidence was appraised for its validity. Several series
of patients published in peer reviewed journals, on patients with pemphigus vulgaris,
pemphigus foliaceus, bullous pemphigoid, cicatricial pemphigoid and epidermolysis bullosa
aquisita, were evaluated for the purpose of this study. A total of 175 patients were identified.
Comparisons were made pre and psot IVIg therapy. These included: clinical response,
recurrence rates, side effects from conventional immunosuppressive therapy (CIST),
hospitalization, duration and frequency of remission and quality of life. Statistical analysis
of these objective parameters indicated that IVIg was effective and superior to CIST. Further
validation of the efficacy comes from those patients that discontinued IVIg therapy, and had
recurrence of disease. In those who received IVIg again, recovery occurred. In those in whom
it was not resumed, the disease progressed further. Recently pharmacoeconomic analysis has
indicated that in the same patients, IVIg was cost-effective compared to CIST. Response to
IVIg is not uniform. Based on clinical response, induction and maintenance of sustained
remission, patients’ maybe responders, partial responders or non-responders. In conclusion,
the efficacy of IVIg for treating AMBDs is evidence based.
Defining clinical disease markers in pemphigus
Victoria P. Werth, Sara Dick, and the PV Definitions Group
The University of Pennsylvania, Philadelphia V.A. Hospital, Philadelphia, PA 19104
Pemphigus vulgaris (PV) is a rare, chronic, potentially life-threatening, acquired autoimmune
vesiculobullous disorder. Although our scientific knowledge of PV is quickly advancing and
our armamentarium of therapies is rapidly growing, there is still a pronounced lack of well-
designed studies and evidence-based practice guidelines. This dearth is not surprising given
the rarity of the disease, as well as the absence of common terms, endpoints, and
measurements to assess disease extent, activity, severity, and therapeutic response. The
recognized need for common definitions and measurements for PV was addressed during a
workshop organized by Dr. Lowell Goldsmith and held at the international NIH Pemphigus
meeting in June 2005. Subsequently, a PV Definitions Committee was organized and
convened during the American Academy of Dermatology meeting in San Francisco held in
March 2006. The committee was comprised of dermatologists with expertise and special
interests in pemphigus. During the course of two days, there was (1) a systematic review of the
terms and measurements used in the pemphigus literature and in ongoing PV studies, (2) an
agreement regarding the definitions of endpoints, complete and partial remission, relapse/
flare, and failure, and (3) an active discussion and proposals for common measurements of the
extent of disease, disease activity, and the intensity of therapy. Those unable to attend the
meeting were contacted by email. A consensus statement with the agreed upon definitions for
PV is being developed. A subsequent meeting in May 2006 evolved options for disease
activity and severity outcome measures. The formation of the PV Definitions Committee, a
consensus statement with agreed upon common definitions, and the ongoing discussion and
refinement of proposed common measurements for PV are the initial and necessary steps
towards progress in the clinical evaluation and therapy of PV. Further progress and
advancement will require a continued collaborative effort.
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